Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
EF Adventures Expands Exclusive Cycling Tour Offerings during the Tour de France and Tour de France Femmes avec Zwift for 2026
-
Aronora Appoints Industry Leaders to Drive Next Phase of Growth
-
AIResumeBuilder.com Survey: 9 in 10 Gen Z Can't Imagine Life Without ChatGPT
-
Enara Bio Enters 2026 with Dark Antigen Licensing to Boehringer Ingelheim, Appointment of Chief Medical Officer and Plans to Advance DARKFOX T-cell Engager into First-in-Human Studies
-
Corero Network Security Appoints Michelle Ragusa-McBain as Vice President of Channel Sales
-
Dunlop Aircraft Tyres Appoints Lee Timbrell as Chief Commercial Officer
-
Otis Selected for Major Escalator Modernization Across London Underground Network
-
Karsan Makes a Strong Impact at CES 2026 with Field-Proven Autonomous Solutions
-
InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M
-
TD SYNNEX Reports Record Fiscal 2025 Fourth Quarter Results
-
Neogen Announces Second-Quarter 2026 Results
-
Coincheck Group Signs Agreement to Acquire 3iQ, a Global Pioneer in Digital Asset Investment Solutions
-
VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS
-
Osel Enters Agreement with SWOG Cancer Research Network for First-Ever Pivotal Trial of a Microbiome-Based Therapy in Oncology
-
Bidgely Redefines Energy AI in 2025: From Machine Learning to Agentic AI
-
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
-
Protege Raises $30 Million Led by a16z to Unlock Access to Data for AI Development
-
Obita Completes Pre-A Round, Raising Nearly US$30 Million Across Two Rounds
-
Echo Water Unveils the Echo One: An Ultra-Pure Hydrogen Water System
-
GlycoEra Appoints Petra Duda, M.D., Ph.D., as Chief Medical Officer to Advance Precision Immune Degrader Pipeline
-
TransactionTree Appoints Kevin Saum as Chief Executive Officer to Lead Next Phase of Growth
-
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
-
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and He
-
VIP Play, Inc. Announces Strategic Entry into Daily Fantasy Sports Market
-
MSC Income Fund Announces Fourth Quarter 2025 Private Loan Portfolio Activity
-
Tubulis Appoints Charles Fuchs, MD as Chief Medical Officer to Lead Clinical Strategy and Pipeline Development
-
Enhanced Digital Group Announces Series A Financing
-
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
-
Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
-
Canopy Growth Announces Strategic Recapitalization Transactions Significantly Strengthening Balance Sheet to Support Growth Strategy
-
Main Street Announces Fourth Quarter 2025 Private Loan Portfolio Activity
-
Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets
-
Cloopen Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
-
Vertiv Expects Powering Up for AI, Digital Twins and Adaptive Liquid Cooling to Shape Data Center Design and Operations
-
Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases
-
The N2 Company Celebrates 10 Years of Giving, $30 Million Donated to Fight Human Trafficking
-
PlusAI on Track to Launch Factory-Built Commercial Autonomous Trucks Next Year
-
Tisento Therapeutics Completes Enrollment in PRIZM, a Global Phase 2b Study of Zagociguat for the Treatment of MELAS
-
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
-
Vizgen Announces $48 Million Financing
-
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
-
JOYBEES WINS TWO GLOBAL FOOTWEAR AWARDS
-
NIQ and Kodiak Announce Retail Measurement Agreement to Drive Breakfast Category Growth
-
Lantronix to Attend 28th Annual Needham Growth Conference on Jan. 13, 2026
-
RELEX Solutions Launches Deal Management for Smarter Collaborative Promotion Planning
-
Lumexa Imaging Achieves Record De Novo Expansion in 2025
-
Tanger Announces Pricing of Upsized Exchangeable Senior Notes Offering
-
K1x and Juno Announce Strategic Partnership to Provide Industry-Leading Tax Automation
-
U.S. Army Selects Striveworks for AI Test and Evaluation
-
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease
